Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock

Key Points

• Moderna insider Shannon Klinger sold 3,471 shares for approximately $485,766 at an average price of $139.95. The transaction was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding from vested equity awards, leaving Klinger with 74,129 shares.
• Moderna shares traded at $148.87, down 1.3%, with a market capitalization of about $59.4 billion. The company reported a quarterly loss of $1.97 per share but exceeded estimates and generated $145 million in revenue.
• Analyst sentiment remains mixed: the consensus rating is Hold with an average price target of $76.72, while recent developments—including positive melanoma trial results and FDA approval of its mRNA flu vaccine—are offset by valuation concerns and rising competition.

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) insider Shannon Klinger sold 3,471 shares of the business's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider directly owned 74,129 shares of the company's stock, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Moderna Stock Down 1.3%

MRNA stock traded down $1.94 during trading on Thursday, reaching $148.87. 13,253,486 shares of the company traded hands, compared to its average volume of 11,625,410. The business has a 50 day simple moving average of $82.40 and a 200 day simple moving average of $62.12. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $176.66. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The company has a market capitalization of $59.43 billion, a price-to-earnings ratio of -18.63 and a beta of 1.10.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same period in the previous year, the company posted ($2.13) earnings per share. The firm's revenue was up 2.1% on a year-over-year basis. On average, equities research analysts anticipate that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that Phase 3 INTerpath-001 met its primary recurrence-free-survival endpoint in patients with resected stage IIB–IV melanoma. The result marked the first positive Phase 3 trial for an mRNA-based cancer therapy and significantly strengthened Moderna’s oncology strategy. Moderna and Merck melanoma trial announcement
• Positive Sentiment: The FDA approved Moderna’s mFlusiva mRNA flu vaccine for adults, adding a commercial opportunity beyond COVID-19 and cancer. FDA approves Moderna mRNA flu vaccine
• Positive Sentiment: Brookline Capital Markets raised its 2026–2028 EPS forecasts and maintained a Buy rating, projecting Moderna could reach positive earnings in 2028. Moderna analyst estimates
• Neutral Sentiment: Investor interest remains elevated: Bamco bought roughly 2 million Moderna shares in the second quarter, while options activity and short-squeeze speculation point to continued bullish trading interest. Bamco Moderna investment
• Negative Sentiment: Rothschild & Co. Redburn downgraded Moderna from Neutral to Sell, arguing the cancer-vaccine rally has made the stock overvalued. Its $81 price target implies substantial downside from current levels, despite being raised from $40. Rothschild Moderna downgrade
• Negative Sentiment: GSK advanced a competing mRNA flu vaccine into Phase 3 after reporting stronger immune responses in Phase 2, raising future competitive risk for mFlusiva. GSK mRNA flu vaccine development

Analysts Set New Price Targets

Several analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft began coverage on Moderna in a report on Friday, August 28th. They set a "hold" rating for the company. Piper Sandler reiterated an "overweight" rating on shares of Moderna in a research note on Monday, August 3rd. Loop Capital set a $135.00 price target on Moderna in a report on Wednesday, August 19th. The Goldman Sachs Group boosted their price target on Moderna from $67.00 to $120.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 19th. Finally, Morgan Stanley lifted their target price on shares of Moderna from $39.00 to $89.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 20th. Seven investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $76.72.

Institutional Trading of Moderna

Several hedge funds and other institutional investors have recently bought and sold shares of MRNA. TD Waterhouse Canada Inc. increased its holdings in shares of Moderna by 2.6% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company's stock worth $246,000 after purchasing an additional 85 shares during the period. Assetmark Inc. grew its position in Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company's stock worth $41,000 after buying an additional 208 shares in the last quarter. New Mexico Educational Retirement Board grew its position in Moderna by 1.9% during the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company's stock worth $463,000 after buying an additional 300 shares in the last quarter. IFP Advisors Inc increased its stake in Moderna by 5.4% during the fourth quarter. IFP Advisors Inc now owns 6,785 shares of the company's stock valued at $200,000 after acquiring an additional 348 shares during the period. Finally, Empowered Funds LLC increased its stake in Moderna by 2.6% during the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company's stock valued at $405,000 after acquiring an additional 353 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source